Revive Therapeutics Announces Results of Annual Shareholder Meeting

Core Points - Revive Therapeutics Ltd. held its annual and special meeting of shareholders on March 18, 2025, where voting results were announced [1] - Shareholders elected new board members and approved the continuation of the 10% rolling incentive stock option plan [2][6] - The Board of Directors decided not to proceed with a proposal to amend the Company's articles of incorporation for share consolidation based on shareholder feedback [2] Company Overview - Revive Therapeutics is focused on developing therapeutics for infectious diseases, rare disorders, and medical countermeasures [3] - The company is leveraging regulatory incentives from the FDA, including Emergency Use Authorization and Breakthrough Therapy designations, to advance its drug development [3] - Current research includes the use of Bucillamine for nerve agent exposure and long COVID, as well as Psilocybin-based therapeutics [3]